Reports from the Field

Once-daily migraine treatment approved

The Food and Drug Administration recently approved Depakote ER (divalproex sodium extended-release tablets), a once-daily formulation for the prevention of migraine headaches in adults by Abbott Laboratories in Abbott Park, IL.

In a 16-week, multi-center, double-blind, placebo-controlled study of 107 migraine sufferers, patients receiving Depakote had a mean four-week migraine headache rate of 3.5 compared to a mean rate of 5.7 for the placebo group. In a similarly designed second trial of 176 patients, Depakote-treated patients had a mean four-week migraine rate of 3.2 compared to a mean rate of 4.5 for the placebo group.

For more information on Depakote, visit the Abbott Web site at www.abbott.com.